Clinical Trial

Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma

Study acronym: Isa-RVD
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the stringent Complete Response (sCR) rate by the end of two cycles of induction treatment, defined as the proportion of patients who have achieved sCR, according to International Myeloma Working Group (IMWG) criteria, by the end of two cycles of induction treatment.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2021-11-05; most recent amendment 2025-07-04.
Status change: Recruiting → Active, Not Recruiting 2025-04-08
Status change: Not Yet Recruiting → Recruiting 2022-07-29
Trial Details
NCT Number NCT05123131
Lead Sponsor Cancer Trials Ireland
Collaborators: Sanofi, Dana-Farber Cancer Institute
Conditions Multiple Myeloma
Enrollment 54 participants
Start Date 2022-04-01
Primary Completion 2025-06-24 (estimated)
Study Completion 2027-12-15 (estimated)
Updated on ClinicalTrials.gov 2025-07-08